Outcome of patients treated with IVE/MTX (n = 26) versus patients treated with anthracycline-based chemotherapy from population-based evaluation (n = 31)
| . | IVE/MTX, n (%) . | Anthracycline-based chemotherapy, n (%) . | P* . |
|---|---|---|---|
| Response to treatment | |||
| CR | 17 (65) | 13 (42) | .06 |
| PR | 1 (4) | 0 (0) | |
| Failure | 8 (31) | 18 (58) | |
| Death | 10 (39) | 25 (81) | .001 |
| Death from lymphoma | 8 (31) | 19 (61) | .005 |
| . | IVE/MTX, n (%) . | Anthracycline-based chemotherapy, n (%) . | P* . |
|---|---|---|---|
| Response to treatment | |||
| CR | 17 (65) | 13 (42) | .06 |
| PR | 1 (4) | 0 (0) | |
| Failure | 8 (31) | 18 (58) | |
| Death | 10 (39) | 25 (81) | .001 |
| Death from lymphoma | 8 (31) | 19 (61) | .005 |
IVE/MTX indicates ifosfamide, vincristine, etoposide/methotrexate; CR, complete remission; and PR, partial remission.
Patients treated with IVE/MTX versus patients treated with anthracycline-based chemotherapy from population-based evaluation.